Phase 1/2 × Recruiting × Carcinoma, Hepatocellular × Clear all Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
Phase 1/2 Recruiting
92 enrolled
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
Phase 1/2 Recruiting
64 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
Phase 1/2 Recruiting
15 enrolled
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase 1/2 Recruiting
280 enrolled
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Phase 1/2 Recruiting
85 enrolled
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/2 Recruiting
147 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Phase 1/2 Recruiting
138 enrolled
Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
Phase 1/2 Recruiting
144 enrolled
ARYA-3
Phase 1/2 Recruiting
20 enrolled
Study of GV20-0251 in Participants With Solid Tumor Malignancies
Phase 1/2 Recruiting
350 enrolled
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
862 enrolled
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/2 Recruiting
126 enrolled
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
Phase 1/2 Recruiting
45 enrolled
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma
Phase 1/2 Recruiting
45 enrolled
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
Phase 1/2 Recruiting
40 enrolled
HAICI
Phase 1/2 Recruiting
10 enrolled
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Phase 1/2 Recruiting
24 enrolled
ARYA-2
Phase 1/2 Recruiting
15 enrolled
To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
Phase 1/2 Recruiting
120 enrolled
MacroTrans
Phase 1/2 Recruiting
48 enrolled
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Phase 1/2 Recruiting
358 enrolled
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Phase 1/2 Recruiting
25 enrolled
A Study of PTX-9908 Injection for Non-resectable HCC with TACE
Phase 1/2 Recruiting
50 enrolled
Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma
Phase 1/2 Recruiting
20 enrolled
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
Phase 1/2 Recruiting
150 enrolled
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Phase 1/2 Recruiting
105 enrolled
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
Phase 1/2 Recruiting
52 enrolled
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Phase 1/2 Recruiting
48 enrolled